Avid Bioservices Inc (CDMO)

[keep_trying]

Seamoss, your $5.5 billion market cap figure falls into the range of valuation of Imclone and Vertex when their drugs got market recognition. I don't know if the 275 million shares is where PPHM will end up.

The second part of Pete's question is value when Bavi goes to approved drug status. A multiple kicks in then, but I tend to agree with Volgoat that PPHM may see a buy out first. It only matters to an investor if they are anxious to move on. It will take quite a while to get Bavi to approved drug status, but the scenario you describe could be within the next year.

Was it you that had estimated Avid production run costs a while back? Maybe when the Q results are posted, you can take another stab at estimating Halozyme contract value?
Using your $70 million Avid revenue figure and applying a price to sales ratio of 20 gives valuation of $1.5 billion or about $7.50 per share.
Best wishes and IMO.
KT